Interventioneller Verschluss des linken Vorhofohrs – Aktueller Stand der Vorhofokkluder

Vorhofflimmern (VHF) ist die häufigste Herzrhythmusstörung und ist mit einem erhöhten thrombembolischen Schlaganfallrisiko kardialen Ursprungs assoziiert. Der interventionelle Verschluss des linken Vorhofohrs (LAA) mittels LAA-Okkluder ist nicht nur sicher und mit hoher Erfolgsrate durchführbar, sondern ist gleichzeitig eine gute Alternative zur oralen Antikoagulation (OAK), insbesondere für Vorhofflimmer-Patienten, bei denen Kontraindikationen für die OAK vorliegen, die ein hohes Risiko für einen Schlaganfall und/oder Blutung haben sowie für Patienten, die unter OAK einen Schlaganfall und/oder eine schwerwiegende Blutungskomplikation erleiden. Diese Übersichtsarbeit schlussfolgert, dass der interventionelle LAA-Verschluss eine gute Alternative zur OAK ist, insbesondere beugt er bei Patienten einen Schlaganfall vor, die Probleme mit der OAK haben. In den nächsten Jahren werden eine Reihe von neuen LAA-Okkludern auf den Markt drängen. Die Frage, ob technische Unterschiede und Unterschiede im technischen Implantationsergebnis wie etwa Okkluder-Undichtigkeit klinische Ereignisse beeinflussen, wird man erst beantworten können, wenn mehr Langzeiterfahrung an größeren Patienten-Kollektiven vorliegt. Ebenso steht der direkte Vergleich zwischen LAA-Okkluder und den neuen OAK aus.

Atrial fibrillation (AF) is the most common form of cardiac arrhythmia and is associated with an increased risk of thromboembolic stroke of cardiac origin. The transcatheter occlusion of left atrial appendage (LAA) with a LAA-device cannot only be performed safely and with high success rate, but is simultaneously a good alternative to oral anticoagulation (OAC), in particular for AF-patients with contraindications for OAC, with high stroke risk and/or high bleeding risk, as well as for AF-patients who have a history of stroke and/or severe hemorrhage during OAC. This review concludes that the transcatheter occlusion of LAA is a good alternative to OAC, it prevents stroke in particular in patients who have problems with OAC. In the next years several new LAA occluders will come to the market. To answer the question, if technical differences and differences in technical implantation like leak at the device result in negative clinical outcome, long-term experience in greater number of patients is needed. The direct comparison LAA occlusion versus new OAC is also pending.

Key words

Atrial fibrillation - left atrial appendage - transcatheter occlusion - thromboembolic stroke - severe hemorrhage

• Literatur

• 1 Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375
• 2 Beinart R, Heist EK, Mansour M et al. Left Atrial Appendage Dimensions Predict the Risk of Stroke/TIA in Patients With Atrial Fibrillation. J Cardiovasc Electrophysiol 2010; 22: 10-15
• 3 Thambidorai SK, Murray RD, Klein AL et al. Utility of transesophageal echocardiography in identification of thrombogenic milieu in patients with atrial fibrillation (an ACUTE ancillary study). Am J Cardiol 2005; 96: 935-941
• 4 Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
• 5 Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol 2007; 6: 981-993
• 6 Di Biase L, Santangeli P, Gaita F et al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol 2012; 60: 531-538
• 7 Nieuwlaat R, Capucci A, Crijns HJ et al. HJGM on behalf of the Euro Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries. The Euro Heart Survey on atrial fibrillation. Eur Heart J 2005; 26: 2422-2434
• 8 Granger CB, Alexander JH, Wallentin L et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
• 9 Madden JL. Resection of the left auricular appendix; a prophylaxis for recurrent arterial emboli. J Am Med Assoc 1949; 140: 769-772
• 10 Odell JA, Blackshear JL, Orszulak TA et al. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction?. Ann Thorac Surg 1996; 61: 565-569
• 11 Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534-542
• 12 Viles-Gonzalez JF, Kar S, Douglas P et al. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol 2012; 59: 923-929
• 13 Reddy V, Doshi S, Sievert H et al. Long term results of PROTECT-AF: the mortality effects of left atrial appendage closure versus warfarin for stroke prophylaxis in AF. Heart Rhythm Society 2013 Scientific Sessions; May 9, 2013; Denver, CO.
• 14 Presented by Dr. David Holmes at ACC 2013, San Francisco, March 9th, 2013. http://www.afibprofessional.cardiosource.org/Science-And-Quality/Clinical-Trials/P/PREVAIL.aspx?pageview=afib&w_nav=Search&WT.oss=prevail&WT.oss_r=310&
• 15 Reddy VY, Möbius-Winkler S, Sievert H et al. Left Atrial Appendage Closure with the Watchman Device in Patients with a Contraindication for Oral Anticoagulation: ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology (ASAP Study). J Am Coll Cardiol DOI: 10.1016/j.jacc.2013.035. 2013;
• 16 Park J-W, Bethencour A, Leithäuser B et al. Left atrial appendage closure with Amplatzer cardiac plug in AF: initial European experience. Catheter Cardiovasc Interv 2011; 77: 700-706
• 17 Park J-W, Sievert H, Omran H et al. TCT-112 Interim Data from Amplatzer Cardiac Plug Registry. JACC 2011; 58 (Suppl. 01)
• 18 Tzikas A, Shakir S, Park J-W et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention online publish-ahead-of-print January 2015;
• 19 Kefer J, Tzikas A, Park J-W et al. Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation. Int J Cardiol 2016; 207: 335-340